PT. RICHMOND, Calif., Feb. 7 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the 10th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 10:15 AM Eastern Time.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
deriving significant new patient benefits from proven CNS drugs. Transcept
development projects leverage new understanding of CNS conditions to
provide additional uses and enhanced clinical benefits for existing active
agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate
lozenge), is a low dose sublingual formulation of zolpidem for the
treatment of insomnia in patients who awaken in the middle of the night and
have difficulty returning to sleep. Phase 3 clinical trials have been
completed for Intermezzo(R) and Transcept plans to submit an NDA in the
third quarter of 2008. Another product being developed by Transcept is
TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for
the treatment of dopamine associated psychiatric disorders. TO-2060 has
recently completed a successful dose ranging trial for the treatment of
alcohol use disorder and a full clinical development program has begun. For
further information, please visit the company's website at:
http://www.transcept.com.
Contacts:
Transcept Pharmaceuticals, Inc.
Michael Gill
Director of Communications
(510) 215-3575
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
'/>"/>
| SOURCE Transcept Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine news :
1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |